Biocept Announces Panel Presentation at Cantor Fitzgerald Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced that President and Chief Executive Officer Michael Nall will participate in a panel discussion at the Cantor Fitzgerald Inaugural Healthcare Conference being held Wednesday, July 8, 2015, at the Le Parker Meridien Hotel in New York City. The panel, “Liquid Biopsies: The benefits and challenges ahead for CTCs, ctNDA, and exosomes,” will be held at 2:30 p.m. Eastern time.

“We appreciate Cantor Fitzgerald’s focus on the promising field of liquid biopsy and are delighted to participate on this panel,” said Mr. Nall. “We see a clear benefit of using a simple blood draw to help physicians personalize their patients’ treatment by monitoring disease status to adjust treatment when necessary. At Biocept, our proprietary platform has the ability to capture and analyze both circulating tumor cells (CTCs) and cell free circulating tumor-associated DNA (ctDNA), and we have commercialized novel test panels for breast, gastric and lung cancers.”

About Biocept

Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept’s technology platform captures and analyzes circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (ctDNA). Biocept currently offers OncoCEE-GA™ for gastric cancer, OncoCEE-BR™ for breast cancer and OncoCEE-LU™ for non-small cell lung cancer, and plans to introduce CLIA-validated tests for colorectal, melanoma, prostate and other solid tumors in the near term.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our impact on the field of personalized medicine and diagnostic strategies, and planned future offerings, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150706005238/en/

Investor Contact:
LHA
Jody Cain, 310-691-7100
[email protected]

Source: Biocept, Inc.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• YY Group Holding (YYGH) Closes $5M IPO
• Advent Technologies (ADN) Receives Nasdaq Notice on Late Filing of its Form 10-K